| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5654791 | Clinical Immunology | 2017 | 22 Pages |
Abstract
Similar results were obtained after in vitro addition of increasing amounts of eculizumab to a control serum (in vitro APH50Â >Â 60% and AP100Â >Â 20%). We also showed that ELISA was less sensitive than HA.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bénédicte Puissant-Lubrano, Sylvain Puissochet, Nicolas Congy-Jolivet, Dominique Chauveau, Stéphane Decramer, Arnaud Garnier, Antoine Huart, Nassim Kamar, David Ribes, Antoine Blancher,